Board Properly Declared Copaxone Patents Invalid, Federal Circuit Finds
Mealey's (October 15, 2018, 1:25 PM EDT) -- WASHINGTON, D.C. — On the same day it affirmed a Delaware federal judge’s determination of invalidity with regard to four patents covering the multiple sclerosis drug Copaxone, the Federal Circuit U.S....
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login